Abstract
Conventional antipsychotic drugs, which have been used for a half century to treat a range of major psychiatric disorders like schizophrenia, are being replaced by modern “atypical antipsychotics”. Although the term “atypical” has been applied broadly to antipsychotic drugs marketed in the past decade, these newer drugs are strikingly heterogeneous in chemical, pharmacological, and clinical points of view. Recently, much attention has been directed to partial dopamine receptor agonists as promising atypical antipsychotics with properties of “dopamine system stabilizers”, which behave either as agonists or antagonists depending on the functional state of the dopamine receptors. Aripiprazole (OPC-14597) is the first and unique antipsychotic drug with such pharmacological properties commercially available in US, Europe, and most recently in Japan. In the present article, the term “atypicality” is critically revisited, and the place of partial dopamine receptor agonists in atypical antipsychotics is overviewed with special reference to the intrinsic activities appropriate for treating the schizophrenic patients with greatest efficacy and least liability of adverse effects such as extrapyramidal symptoms.
Keywords: Atypical antipsychotics, aripiprazole, dopamine receptor, partial agonist, intrinsic activity, presynaptic autoreceptor, schizophrenia, dopamine system stabilizer
Central Nervous System Agents in Medicinal Chemistry
Title: Partial Dopamine Receptor Agonists as Newer Atypical Antipsychotics:Intrinsic Activity Appropriate for Treatment of Schizophrenic Patients
Volume: 7 Issue: 3
Author(s): Yuji Odagaki
Affiliation:
Keywords: Atypical antipsychotics, aripiprazole, dopamine receptor, partial agonist, intrinsic activity, presynaptic autoreceptor, schizophrenia, dopamine system stabilizer
Abstract: Conventional antipsychotic drugs, which have been used for a half century to treat a range of major psychiatric disorders like schizophrenia, are being replaced by modern “atypical antipsychotics”. Although the term “atypical” has been applied broadly to antipsychotic drugs marketed in the past decade, these newer drugs are strikingly heterogeneous in chemical, pharmacological, and clinical points of view. Recently, much attention has been directed to partial dopamine receptor agonists as promising atypical antipsychotics with properties of “dopamine system stabilizers”, which behave either as agonists or antagonists depending on the functional state of the dopamine receptors. Aripiprazole (OPC-14597) is the first and unique antipsychotic drug with such pharmacological properties commercially available in US, Europe, and most recently in Japan. In the present article, the term “atypicality” is critically revisited, and the place of partial dopamine receptor agonists in atypical antipsychotics is overviewed with special reference to the intrinsic activities appropriate for treating the schizophrenic patients with greatest efficacy and least liability of adverse effects such as extrapyramidal symptoms.
Export Options
About this article
Cite this article as:
Odagaki Yuji, Partial Dopamine Receptor Agonists as Newer Atypical Antipsychotics:Intrinsic Activity Appropriate for Treatment of Schizophrenic Patients, Central Nervous System Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152407781669125
DOI https://dx.doi.org/10.2174/187152407781669125 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atypical Antipsychotics: Pharmacokinetics, Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry Novel Insight into Cholinergic Factors Associated with Schizophrenia and Autoimmunity
Current Immunology Reviews (Discontinued) Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry The Large Conductance Calcium- and Voltage-activated Potassium Channel (BK) and Epilepsy
CNS & Neurological Disorders - Drug Targets The Concept of “Neuroprotection” in Neurological Diseases
Current Neuropharmacology Membrane Pathology in Schizophrenia: Implication for Arachidonic Acid Signaling
Current Medicinal Chemistry - Central Nervous System Agents Effects of Thyroid Hormones on Memory and on Na+, K+-ATPase Activity in Rat Brain
Current Neurovascular Research Retraction Notice: Clinical Strategies for Preventing Postoperative Nausea and Vomiting After Middle Ear Surgery in Adult Patients
Current Drug Safety Gene Frequency of <i>CYP2D6*4</i> and <i>*10</i> Variants in Karachi Population
Current Pharmacogenomics and Personalized Medicine Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine New Insight into the Therapeutic Role of 5-HT1A Receptors in Central Nervous System Disorders
Central Nervous System Agents in Medicinal Chemistry Current Progresses on Nanodelivery Systems for the Treatment of Neuropsychiatric Diseases: Alzheimer’s and Schizophrenia
Current Pharmaceutical Design Serotonin 5-HT<sub>1A</sub> Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs
Current Pharmaceutical Design Effect of Brain Derived Neurotrophic Factor (BDNF) Gene Variants on Therapeutic Response and the Risk for Schizophrenia
Current Pharmacogenomics Dual Ligands Targeting Dopamine D2 and Serotonin 5-HT<sub>1A</sub> Receptors as New Antipsychotical or Anti-Parkinsonian Agents
Current Medicinal Chemistry COMMENTARY: Magnetic Resonance Techniques Applied to Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Pharmacogenomic-Guided Rational Therapeutic Drug Monitoring: Conceptual Framework and Application Platforms for Atypical Antipsychotics
Current Medicinal Chemistry Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology Psychiatric Disorders and TRP Channels: Focus on Psychotropic Drugs
Current Neuropharmacology Rhinosinusitis in the Pediatric Patient with Cystic Fibrosis
Current Pediatric Reviews